Oracle Health Sciences Adds 93 Emerging Biopharma Customers
Oracle Health Sciences announced that 93 emerging biopharma organizations worldwide have become new customers in the past year. These include sponsors Accera and NewLink Genetics and CROs FMD K&L and 4C Pharma Solutions.
- FMD K&L adopted Oracle Health Sciences InForm to help ensure data accuracy and efficiencies.
- Accera, a biotechnology company focused on conditions affecting the central nervous system, uses cloud-based Oracle Health Sciences ClearTrial Plan and Source Enterprise Edition Cloud Service to model scenarios for future trials.
- 4C Pharma Solutions and NewLink Genetics use Oracle Argus Safety for insight into product-safety issues, improved productivity, and streamlined safety reporting.
Read the full release.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
